TAK, US8740602052

Takeda schedules October 29 results call for Takeda stock

Published on 10/15/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TAK-881 cut infusion volume 50.00 percent on October 14, 2026. Takeda stock posted JPY 201.4 billion in first-quarter operating profit.

Clinical data shape the timeline

Takeda scheduled its fiscal 2026 second-quarter results call for October 29, 2026.
TAK-881 reduced infusion volume by 50.00 percent in data presented on October 14, 2026.
Takeda stock traded at EUR 17.10 at 10:38 a.m. CEST at Lang & Schwarz on October 15, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda stock (ISIN US8740602052) traded at EUR 17.10 at Lang & Schwarz on October 15, 2026 at 10:38 a.m. CEST. Takeda announced on October 15, 2026 that it will present fiscal 2026 second-quarter results on October 29, 2026.

October 29 sets the next test

The scheduled call gives investors a fixed date for the next operating update. Takeda's first-quarter revenue for fiscal 2026 was JPY 1.2 trillion, while operating profit was JPY 201.4 billion. Net income attributable to common shareholders reached JPY 113.2 billion for the same period.

The company will host the presentation and question-and-answer session from 7:00 p.m. to 8:15 p.m. JST on October 29, 2026. Takeda's investor page also identifies the event as the fiscal 2026 second-quarter earnings announcement.

What does the pipeline add?

Takeda presented TAK-881 results on October 14, 2026. The investigational treatment delivered the same immunoglobulin dose in 50.00 percent less volume than HYQVIA and shortened median infusion time by 42.60 percent, or 56.20 minutes, at one infusion site. The study included 43 randomized participants, with 9 discontinuations, or 20.90 percent.

The chronology shows how the earnings date now sits beside a late-stage pipeline update. On July 30, 2026, Takeda reported earnings per share of USD 0.23 against a USD 0.17 estimate, according to Gekko. On October 14, 2026, the TAK-881 data showed a 50.00 percent volume reduction. On October 15, 2026, Takeda set the October 29 results call.

Dates that matter next

Takeda's oncology data are scheduled for October 23, 2026, while the fiscal 2026 second-quarter results call is set for October 29, 2026, according to Gekko and Takeda.

Stock trades ahead of results

Takeda's market value was USD 60.3 billion as of October 15, 2026. The primary listing is split between the Tokyo Stock Exchange and the New York Stock Exchange, with the American Depositary Share trading under TAK. The company operates across gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

At Lang & Schwarz, Takeda stock was trading at EUR 17.10 on October 15, 2026 at 10:38 a.m. CEST. The quote is an intraday indication for German-based investors; the next company-specific test is the October 29 results release. The further course of trading is shown by the continuously updated real-time quote of Takeda stock.